<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03807583</url>
  </required_header>
  <id_info>
    <org_study_id>ID-RCB 2018-00145-50</org_study_id>
    <nct_id>NCT03807583</nct_id>
  </id_info>
  <brief_title>Plasma Amino Acid Levels After Protein Ingestion or Amino Acid Injection During Dialysis</brief_title>
  <official_title>Prospective, Monocentric, Open-label, Randomized Study Comparing Intradialytic Plasma Kinetics of Amino Acids After Administration Per os of Renoral® and Intravenous Administration of Amino Acids.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indigo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioFortis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indigo Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare intradialytic plasma kinetics of amino acids after&#xD;
      administration per os of Renoral or intravenous administration of amino acids in patients&#xD;
      with end-stage renal disease treated with hemodialysis maintenance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This clinical study is a monocentric, randomized, open-label, 3 parallel arms, and controlled study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma total amino acid concentration</measure>
    <time_frame>Day 60; Time 240 minutes of the kinetic</time_frame>
    <description>The efficacy of the test product will be evaluated by comparing this criterion between the RENORAL® and AMINOVEN® groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma total amino acid concentration</measure>
    <time_frame>Day 60; Time 240 minutes of kinetics</time_frame>
    <description>Comparison between the RENORAL® group and the plasma total amino acid concentration control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma total amino acid concentration</measure>
    <time_frame>Time 0 minutes, Time 60 minutes and Time 120 minutes of kinetics</time_frame>
    <description>Comparison between the RENORAL® group and each AMINOVEN® group and control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma total amino acid concentration</measure>
    <time_frame>Day 90; Day 120 and Day 150 at time 240 minutes of kinetics</time_frame>
    <description>Comparison between the RENORAL® group and each AMINOVEN® group and control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein catabolism</measure>
    <time_frame>Day 90; Day 120 and Day 150 at time 0 minutes of kinetics</time_frame>
    <description>Plasma urea concentration (mmol.L-1) ;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein catabolism</measure>
    <time_frame>Day 90; Day 120 and Day 150 at time 0 minutes of kinetics</time_frame>
    <description>Plasma creatinine concentration (µmol.L-1);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein catabolism</measure>
    <time_frame>Day 90; Day 120 and Day 150 at time 0 minutes of kinetics</time_frame>
    <description>Standardized protein catabolism rate (nPCR) (g/kg/day):&#xD;
BUN: Blood urea nitrogen is one of the main renal function parameters (mmol/L).&#xD;
ID Refers to the interdialytic period in hours.&#xD;
ID BUN rise refers to the registered change in blood urea nitrogen during the interdialytic period.&#xD;
The two nPCR formulas used are:&#xD;
nPCR Anuric = 0.22 + (0.864 x (ID BUN rise in mg/dL) / (ID hours)) nPCR Total = nPCR Anuric + (Urine urea nitrogen in g x 150) / (ID hours x Weight in kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation degree</measure>
    <time_frame>Day 90; Day 120 and Day 150 at time 0 minutes of kinetics</time_frame>
    <description>Comparison between the RENORAL® group and each AMINOVEN® group and control. Evaluated by plasma CRPus concentration (mg.L-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Day 90, Day 120 and Day 150; At time 0 minute of kinetics</time_frame>
    <description>Plasma albumin concentration (g.L-1) ;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Day 90, Day 120 and Day 150; At time 0 minute of kinetics</time_frame>
    <description>- Plasma prealbumin concentration (g.L-1) ;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Day 90, Day 120 and Day 150; At time 0 minute of kinetics</time_frame>
    <description>- Plasma ferritin concentration (µg.L-1) ;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Day 90, Day 120 and Day 150; At time 0 minute of kinetics</time_frame>
    <description>- Plasma transferrin concentration (ng.L-1) ;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Day 150</time_frame>
    <description>- Body mass index (BMI) (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Day 150</time_frame>
    <description>- Body composition by impedance measurement (Body Composition Monitor / Fresenius Medical Care) analyzed by the following parameters: lean mass (LTM) (kg), fat mass (ATM) (kg) and water overload (OH) (L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>During the week preceding Day 150</time_frame>
    <description>- Total energy intake (average of the 3 food survey days, kcal/day);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>During the week preceding Day 150</time_frame>
    <description>- Protein consumption (average of the 3 food survey days, g/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscular force</measure>
    <time_frame>Day 150</time_frame>
    <description>Evaluated by the gripping force by dynamometry (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of Renoral®</measure>
    <time_frame>Day 60 and Day 150</time_frame>
    <description>Self-administered questionnaire&#xD;
4 questions:&#xD;
Overall, do you like this product? minimum score:1 (I don't like); maximum score: 9 (I like a lot)&#xD;
How do you find the texture of the product? Score 1: Not at all pleasant Score 2: Somewhat unpleasant Score 3: Somewhat pleasant Score 4: Very pleasant&#xD;
What do you think of the practicality of the product? Score 1 - Not practical at all Score 2 - Not very practical Score 3 - Somewhat practical Score 4 - Very practical&#xD;
What do you think of the vanilla flavour of the product? Score 1 - Much too pronounced Score 2 - Somewhat pronounced Score 3 - Just the right way Score 4 - Not strong enough Score 5 - Really not pronounced</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood pressure (mmHg)</measure>
    <time_frame>Day 0 to Day 150 at time 0, 60, 120 and 240 minutes of dialysis</time_frame>
    <description>Security parameters evaluated from Day 0 to Day 150</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood count</measure>
    <time_frame>Day 0 to Day 150 at time 0 minute</time_frame>
    <description>Security parameters evaluated at all visits (from Day 0 to Day 150)</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood sugar</measure>
    <time_frame>Day 0 to Day 150 at time 0 minute</time_frame>
    <description>Security parameters evaluated at all visits (from V0 to V5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Electrolyte balance by ionogram. Blood ionogram expressed in (mmol.L-1), the parameters considered are: Sodium, Potassium, Chlorine, Bicarbonates, Calcium, and Phosphorus.</measure>
    <time_frame>Day 0 to Day 150 at time 0 minute</time_frame>
    <description>Security parameters evaluated at all visits (from V0 to V5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver function (Alkaline Phosphatase concentration)</measure>
    <time_frame>Day 0 to Day 150 at time 0 minute</time_frame>
    <description>Security parameters evaluated at all visits (from V0 to V5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Thyroid function (PTH concentration)</measure>
    <time_frame>Day 0 to Day 150 at time 0 minute</time_frame>
    <description>Security parameters evaluated at all visits (from V0 to V5)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>End Stage Renal Disease on Dialysis (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AMINOVEN® 10%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The AMINOVEN® 10% comparative product is a drug in the form of a 130 mL intravenous infusion solution. This product is composed of amino acids.&#xD;
The product is administered per os during the first hour of dialysis sessions for the duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RENORAL®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The product under study RENORAL® is notified to the DGCCRF with the status of food supplement for medical purposes (FSMP) and specific for renal insufficiency.&#xD;
The product is a beverage packaged in 150 mL aluminum cans. It contains a liquid solution of native milk proteins and partially hydrolyzed whey proteins.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminoven 10%</intervention_name>
    <description>After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:&#xD;
group A: RENORAL® product&#xD;
group B: AMINOVEN® 10% product&#xD;
group C: control group (without intradialytic supplementation)&#xD;
Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care.</description>
    <arm_group_label>AMINOVEN® 10%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>RENORAL</intervention_name>
    <description>After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:&#xD;
group A: RENORAL® product&#xD;
group B: AMINOVEN® 10% product&#xD;
group C: control group (without intradialytic supplementation)&#xD;
Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care.</description>
    <arm_group_label>RENORAL®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women over 18 (limit included),&#xD;
&#xD;
          -  Patients treated with hemodialysis for at least 3 months (limit included),&#xD;
&#xD;
          -  Patient with normal albuminemia ≥ 35 g/L&#xD;
&#xD;
          -  Patient capable and willing to comply with the protocol and willing to give written&#xD;
             informed consent,&#xD;
&#xD;
          -  Patient affiliated to a social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a known food allergy or intolerance,&#xD;
&#xD;
          -  Patient with alcohol consumption ≥ 20 g/day (equivalent to 2 glasses per day),&#xD;
&#xD;
          -  Patient following a specific diet (vegetarian, hypocaloric, restrictive gluten-free&#xD;
             diet....) outside the high-protein diet of the patient with terminal renal&#xD;
             insufficiency or deviant behavior,&#xD;
&#xD;
          -  Pregnant or breastfeeding woman or intending to become pregnant within the next 3&#xD;
             months&#xD;
&#xD;
          -  Patient taking vitamin or mineral supplementation for less than one month,&#xD;
&#xD;
          -  Patient participating in another clinical study or in a period of exclusion from a&#xD;
             previous clinical study;&#xD;
&#xD;
          -  Patient refusing to give written consent,&#xD;
&#xD;
          -  Patient not able to read and understand information, consent or other study related&#xD;
             documents (self-administered questionnaires),&#xD;
&#xD;
          -  Patient unable to give informed consent,&#xD;
&#xD;
          -  Patient deprived of liberty by administrative or judicial decision, under guardianship&#xD;
             or curatorship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RAYMOND AZAR, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL CENTER DUNKERQUE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RAYMOND AZAR, MD</last_name>
    <phone>+333 28 28 53 28</phone>
    <email>Raymond.Azar@ch-dunkerque.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FAHIMA YAHI</last_name>
    <phone>+333 28 28 59 00</phone>
    <phone_ext>6486</phone_ext>
    <email>Fahima.Yahi-Zidat@ch-dunkerque.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Center</name>
      <address>
        <city>Dunkerque</city>
        <zip>59240</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FAHIMA YAHI</last_name>
      <phone>+333 28 28 59 00</phone>
      <phone_ext>6486</phone_ext>
      <email>Fahima.Yahi-Zidat@ch-dunkerque.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 27, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2019</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03807583
org study id: ID-RCB 2018-00145-50
nct id: NCT03807583
lead sponsor: 
collaborator: 
is fda regulated drug: No
is fda regulated device: No
The aim of the study is to compare intradialytic plasma kinetics of amino acids after
      administration per os of Renoral or intravenous administration of amino acids in patients
      with end-stage renal disease treated with hemodialysis maintenance.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: This clinical study is a monocentric, randomized, open-label, 3 parallel arms, and controlled study.
primary purpose: Prevention
masking: None (Open Label)
measure: Plasma total amino acid concentration
time frame: Day 60; Time 240 minutes of the kinetic
description: The efficacy of the test product will be evaluated by comparing this criterion between the RENORAL® and AMINOVEN® groups.
measure: Plasma total amino acid concentration
time frame: Day 60; Time 240 minutes of kinetics
description: Comparison between the RENORAL® group and the plasma total amino acid concentration control group
measure: Plasma total amino acid concentration
time frame: Time 0 minutes, Time 60 minutes and Time 120 minutes of kinetics
description: Comparison between the RENORAL® group and each AMINOVEN® group and control
measure: Plasma total amino acid concentration
time frame: Day 90; Day 120 and Day 150 at time 240 minutes of kinetics
description: Comparison between the RENORAL® group and each AMINOVEN® group and control
measure: Protein catabolism
time frame: Day 90; Day 120 and Day 150 at time 0 minutes of kinetics
description: Plasma urea concentration (mmol.L-1) ;
measure: Protein catabolism
time frame: Day 90; Day 120 and Day 150 at time 0 minutes of kinetics
description: Plasma creatinine concentration (µmol.L-1);
measure: Protein catabolism
time frame: Day 90; Day 120 and Day 150 at time 0 minutes of kinetics
description: Standardized protein catabolism rate (nPCR) (g/kg/day):
BUN: Blood urea nitrogen is one of the main renal function parameters (mmol/L).
ID Refers to the interdialytic period in hours.
ID BUN rise refers to the registered change in blood urea nitrogen during the interdialytic period.
The two nPCR formulas used are:
nPCR Anuric = 0.22 + (0.864 x (ID BUN rise in mg/dL) / (ID hours)) nPCR Total = nPCR Anuric + (Urine urea nitrogen in g x 150) / (ID hours x Weight in kg)
measure: Inflammation degree
time frame: Day 90; Day 120 and Day 150 at time 0 minutes of kinetics
description: Comparison between the RENORAL® group and each AMINOVEN® group and control. Evaluated by plasma CRPus concentration (mg.L-1).
measure: Nutritional status
time frame: Day 90, Day 120 and Day 150; At time 0 minute of kinetics
description: Plasma albumin concentration (g.L-1) ;
measure: Nutritional status
time frame: Day 90, Day 120 and Day 150; At time 0 minute of kinetics
description: - Plasma prealbumin concentration (g.L-1) ;
measure: Nutritional status
time frame: Day 90, Day 120 and Day 150; At time 0 minute of kinetics
description: - Plasma ferritin concentration (µg.L-1) ;
measure: Nutritional status
time frame: Day 90, Day 120 and Day 150; At time 0 minute of kinetics
description: - Plasma transferrin concentration (ng.L-1) ;
measure: Nutritional status
time frame: Day 150
description: - Body mass index (BMI) (kg/m2)
measure: Nutritional status
time frame: Day 150
description: - Body composition by impedance measurement (Body Composition Monitor / Fresenius Medical Care) analyzed by the following parameters: lean mass (LTM) (kg), fat mass (ATM) (kg) and water overload (OH) (L)
measure: Nutritional status
time frame: During the week preceding Day 150
description: - Total energy intake (average of the 3 food survey days, kcal/day);
measure: Nutritional status
time frame: During the week preceding Day 150
description: - Protein consumption (average of the 3 food survey days, g/day)
measure: Muscular force
time frame: Day 150
description: Evaluated by the gripping force by dynamometry (kg)
measure: Acceptability of Renoral®
time frame: Day 60 and Day 150
description: Self-administered questionnaire
4 questions:
Overall, do you like this product? minimum score:1 (I don't like); maximum score: 9 (I like a lot)
How do you find the texture of the product? Score 1: Not at all pleasant Score 2: Somewhat unpleasant Score 3: Somewhat pleasant Score 4: Very pleasant
What do you think of the practicality of the product? Score 1 - Not practical at all Score 2 - Not very practical Score 3 - Somewhat practical Score 4 - Very practical
What do you think of the vanilla flavour of the product? Score 1 - Much too pronounced Score 2 - Somewhat pronounced Score 3 - Just the right way Score 4 - Not strong enough Score 5 - Really not pronounced
measure: Blood pressure (mmHg)
time frame: Day 0 to Day 150 at time 0, 60, 120 and 240 minutes of dialysis
description: Security parameters evaluated from Day 0 to Day 150
measure: Blood count
time frame: Day 0 to Day 150 at time 0 minute
description: Security parameters evaluated at all visits (from Day 0 to Day 150)
measure: Blood sugar
time frame: Day 0 to Day 150 at time 0 minute
description: Security parameters evaluated at all visits (from V0 to V5)
measure: Electrolyte balance by ionogram. Blood ionogram expressed in (mmol.L-1), the parameters considered are: Sodium, Potassium, Chlorine, Bicarbonates, Calcium, and Phosphorus.
time frame: Day 0 to Day 150 at time 0 minute
description: Security parameters evaluated at all visits (from V0 to V5)
measure: Liver function (Alkaline Phosphatase concentration)
time frame: Day 0 to Day 150 at time 0 minute
description: Security parameters evaluated at all visits (from V0 to V5)
measure: Thyroid function (PTH concentration)
time frame: Day 0 to Day 150 at time 0 minute
description: Security parameters evaluated at all visits (from V0 to V5)
arm group label: Control group
arm group type: No Intervention
arm group label: AMINOVEN® 10%
arm group type: Active Comparator
description: The AMINOVEN® 10% comparative product is a drug in the form of a 130 mL intravenous infusion solution. This product is composed of amino acids.
The product is administered per os during the first hour of dialysis sessions for the duration of the study.
arm group label: RENORAL®
arm group type: Experimental
description: The product under study RENORAL® is notified to the DGCCRF with the status of food supplement for medical purposes (FSMP) and specific for renal insufficiency.
The product is a beverage packaged in 150 mL aluminum cans. It contains a liquid solution of native milk proteins and partially hydrolyzed whey proteins.
intervention type: Drug
intervention name: Aminoven 10%
description: After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:
group A: RENORAL® product
group B: AMINOVEN® 10% product
group C: control group (without intradialytic supplementation)
Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care.
arm group label: AMINOVEN® 10%
intervention type: Dietary Supplement
intervention name: RENORAL
description: After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:
group A: RENORAL® product
group B: AMINOVEN® 10% product
group C: control group (without intradialytic supplementation)
Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care.
arm group label: RENORAL®
criteria: 
gender: All
minimum age: 18 Years
maximum age: 100 Years
healthy volunteers: No
last name: RAYMOND AZAR, MD
role: Principal Investigator
affiliation: HOSPITAL CENTER DUNKERQUE
last name: RAYMOND AZAR, MD
phone: +333 28 28 53 28
email: Raymond.Azar@ch-dunkerque.fr
last name: FAHIMA YAHI
phone: +333 28 28 59 00
phone ext: 6486
email: Fahima.Yahi-Zidat@ch-dunkerque.fr
facility: 
status: Recruiting
contact: 
country: France
responsible party type: Sponsor
mesh term: Kidney Failure, Chronic
sharing ipd: No